Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Carboplatin/Docetaxel in Resected NSCLC
NCT00280735Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- May 2004
- Primary completion
- Jul 2011
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and docetaxel in non-small cell lung cancer (NSCLC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Number of Participants Who Completed Four Cycles of the Carboplatin/Docetaxel Regimen at 12 weeks. Started May 2004; status: completed.
02
Drugs
carboplatindocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00280735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00280735.